Glioma, Melatonin, and Radiotherapy

To the Editor:

Accumulative evidence indicates antitumor effects of melatonin in a variety of malignancies (1, 2). Accordingly, Martin et al. have recently reported cell growth inhibition of glioma by melatonin (3). This study is of peculiar interest because melatonin is produced in the brain by the pineal gland. This location of the pineal gland, near the center of the brain, suggests that in addition to hypothalamic-pituitary dysfunctions (4), a melatonin deficiency could also occur in some patients following brain radiotherapy (5). Although the consequences of melatonin deficiency on glioma growth remain to be investigated, the report of Martin et al. have important implications for the development of a possible circadian-based cancer therapy of glioma. Moreover, it highlights the importance of determining the pineal status of patients following brain radiotherapy, by measuring, for example, the melatonin metabolite 6-sulphatoxymelatonin in the first morning urine (6). In addition to its relevance in the follow-up of patients, this dosage could help to further elucidate the link between melatonin and glioma growth.

Didier Wion
François Berger
Institut National de la Sante et de la Recherche Medicale
U318 UJFG, CHU Michallon,
Grenoble, France

Nelly Wion-Barbot
Service Endocrinologie Diabétologie Nutrition
CHU Grenoble
Université J. Fourier
Grenoble, France

References
Glioma, Melatonin, and Radiotherapy

Didier Wion, François Berger and Nelly Wion-Barbot


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/66/12/6457

Cited articles
This article cites 6 articles, 3 of which you can access for free at:
http://cancerres.aacrjournals.org/content/66/12/6457.full#ref-list-1

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.